AngioDynamics, Inc. (ANGO)
USD 9.0
(-3.33%)
USD 9.0
(-3.33%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 317.67 Million USD | -40.36% |
| 2023 | 532.63 Million USD | -3.64% |
| 2022 | 552.75 Million USD | -1.55% |
| 2021 | 561.43 Million USD | -5.72% |
| 2020 | 595.51 Million USD | -28.8% |
| 2019 | 836.43 Million USD | 18.56% |
| 2018 | 705.47 Million USD | -0.35% |
| 2017 | 707.96 Million USD | -2.76% |
| 2016 | 728.06 Million USD | -5.89% |
| 2015 | 773.62 Million USD | -3.32% |
| 2014 | 800.15 Million USD | 1.04% |
| 2013 | 791.88 Million USD | 9.21% |
| 2012 | 725.07 Million USD | 65.71% |
| 2011 | 437.54 Million USD | 3.21% |
| 2010 | 423.92 Million USD | 3.72% |
| 2009 | 408.7 Million USD | -0.01% |
| 2008 | 408.74 Million USD | 6.64% |
| 2007 | 383.28 Million USD | 179.77% |
| 2006 | 137 Million USD | 129.59% |
| 2005 | 59.67 Million USD | 20.0% |
| 2004 | 49.72 Million USD | 83.79% |
| 2003 | 27.05 Million USD | 31.04% |
| 2002 | 20.64 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 493.94 Million USD | -7.26% |
| 2024 FY | 317.67 Million USD | -40.36% |
| 2024 Q3 | 324.84 Million USD | -34.98% |
| 2024 Q2 | 499.62 Million USD | 1.15% |
| 2024 Q4 | 317.67 Million USD | -2.21% |
| 2023 Q4 | 532.63 Million USD | -1.88% |
| 2023 Q3 | 542.84 Million USD | -2.75% |
| 2023 Q2 | 558.2 Million USD | 0.1% |
| 2023 Q1 | 557.65 Million USD | 0.89% |
| 2023 FY | 532.63 Million USD | -3.64% |
| 2022 Q1 | 555.76 Million USD | -1.01% |
| 2022 FY | 552.75 Million USD | -1.55% |
| 2022 Q2 | 554.1 Million USD | -0.3% |
| 2022 Q4 | 552.75 Million USD | 1.76% |
| 2022 Q3 | 543.17 Million USD | -1.97% |
| 2021 Q1 | 583.75 Million USD | -1.97% |
| 2021 Q4 | 561.43 Million USD | -3.57% |
| 2021 Q2 | 588.52 Million USD | 0.82% |
| 2021 Q3 | 582.24 Million USD | -1.07% |
| 2021 FY | 561.43 Million USD | -5.72% |
| 2020 FY | 595.51 Million USD | -28.8% |
| 2020 Q2 | 724.87 Million USD | 5.0% |
| 2020 Q3 | 731.96 Million USD | 0.98% |
| 2020 Q4 | 595.51 Million USD | -18.64% |
| 2020 Q1 | 690.36 Million USD | -17.46% |
| 2019 Q2 | 783.96 Million USD | 12.98% |
| 2019 Q1 | 693.87 Million USD | -1.64% |
| 2019 FY | 836.43 Million USD | 18.56% |
| 2019 Q3 | 777.79 Million USD | -0.79% |
| 2019 Q4 | 836.43 Million USD | 7.54% |
| 2018 FY | 705.47 Million USD | -0.35% |
| 2018 Q1 | 700.34 Million USD | -1.08% |
| 2018 Q2 | 697.8 Million USD | -0.36% |
| 2018 Q3 | 698.42 Million USD | 0.09% |
| 2018 Q4 | 705.47 Million USD | 1.01% |
| 2017 Q3 | 704.31 Million USD | -1.1% |
| 2017 FY | 707.96 Million USD | -2.76% |
| 2017 Q4 | 707.96 Million USD | 0.52% |
| 2017 Q2 | 712.17 Million USD | -2.0% |
| 2017 Q1 | 726.71 Million USD | -0.19% |
| 2016 Q3 | 753.51 Million USD | -0.9% |
| 2016 Q4 | 728.06 Million USD | -3.38% |
| 2016 Q1 | 771.78 Million USD | -0.24% |
| 2016 FY | 728.06 Million USD | -5.89% |
| 2016 Q2 | 760.37 Million USD | -1.48% |
| 2015 FY | 773.62 Million USD | -3.32% |
| 2015 Q4 | 773.62 Million USD | -1.21% |
| 2015 Q3 | 783.13 Million USD | -2.03% |
| 2015 Q2 | 799.33 Million USD | 0.26% |
| 2015 Q1 | 797.29 Million USD | -0.36% |
| 2014 Q2 | 795.49 Million USD | -0.71% |
| 2014 FY | 800.15 Million USD | 1.04% |
| 2014 Q3 | 792.17 Million USD | -0.42% |
| 2014 Q4 | 800.15 Million USD | 1.01% |
| 2014 Q1 | 801.15 Million USD | 1.17% |
| 2013 FY | 791.88 Million USD | 9.21% |
| 2013 Q4 | 791.88 Million USD | -0.58% |
| 2013 Q2 | 778.94 Million USD | 8.49% |
| 2013 Q1 | 717.99 Million USD | -0.98% |
| 2013 Q3 | 796.47 Million USD | 2.25% |
| 2012 Q1 | 439.6 Million USD | 0.47% |
| 2012 Q2 | 443.59 Million USD | 0.91% |
| 2012 Q3 | 446.6 Million USD | 0.68% |
| 2012 Q4 | 725.07 Million USD | 62.35% |
| 2012 FY | 725.07 Million USD | 65.71% |
| 2011 Q3 | 433.39 Million USD | 1.74% |
| 2011 Q1 | 420.35 Million USD | -0.84% |
| 2011 FY | 437.54 Million USD | 3.21% |
| 2011 Q4 | 437.54 Million USD | 0.96% |
| 2011 Q2 | 425.98 Million USD | 1.34% |
| 2010 Q3 | 412.29 Million USD | 1.14% |
| 2010 Q4 | 423.92 Million USD | 2.82% |
| 2010 FY | 423.92 Million USD | 3.72% |
| 2010 Q2 | 407.63 Million USD | -0.4% |
| 2010 Q1 | 409.28 Million USD | 0.14% |
| 2009 Q3 | 400.57 Million USD | 1.94% |
| 2009 Q4 | 408.7 Million USD | 2.03% |
| 2009 FY | 408.7 Million USD | -0.01% |
| 2009 Q2 | 392.95 Million USD | -0.76% |
| 2009 Q1 | 395.97 Million USD | -3.13% |
| 2008 Q2 | 392.82 Million USD | 2.02% |
| 2008 Q4 | 408.74 Million USD | 2.97% |
| 2008 Q3 | 396.93 Million USD | 1.05% |
| 2008 FY | 408.74 Million USD | 6.64% |
| 2008 Q1 | 385.04 Million USD | 0.46% |
| 2007 Q1 | 141.75 Million USD | 3.47% |
| 2007 Q4 | 383.28 Million USD | 1.59% |
| 2007 Q3 | 377.28 Million USD | 153.01% |
| 2007 Q2 | 149.11 Million USD | 5.19% |
| 2007 FY | 383.28 Million USD | 179.77% |
| 2006 Q4 | 137 Million USD | 95.08% |
| 2006 Q2 | 64.23 Million USD | 4.73% |
| 2006 Q1 | 61.33 Million USD | 2.79% |
| 2006 FY | 137 Million USD | 129.59% |
| 2006 Q3 | 70.22 Million USD | 9.32% |
| 2005 Q3 | 53.83 Million USD | 6.87% |
| 2005 Q1 | 48.63 Million USD | -2.2% |
| 2005 Q2 | 50.37 Million USD | 3.58% |
| 2005 FY | 59.67 Million USD | 20.0% |
| 2005 Q4 | 59.67 Million USD | 10.84% |
| 2004 Q4 | 49.72 Million USD | 71.04% |
| 2004 Q3 | 29.07 Million USD | 0.0% |
| 2004 FY | 49.72 Million USD | 83.79% |
| 2003 FY | 27.05 Million USD | 31.04% |
| 2003 Q4 | 27.05 Million USD | 0.0% |
| 2002 FY | 20.64 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 180.36 Million USD | -76.123% |
| AtriCure, Inc. | 613.93 Million USD | 48.256% |
| Avinger, Inc. | 13.77 Million USD | -2206.979% |
| Azenta, Inc. | 2.88 Billion USD | 88.992% |
| BioLife Solutions, Inc. | 412.71 Million USD | 23.029% |
| The Cooper Companies, Inc. | 11.65 Billion USD | 97.275% |
| Daxor Corporation | 34.86 Million USD | -811.038% |
| Ekso Bionics Holdings, Inc. | 28.91 Million USD | -998.523% |
| Femasys Inc. | 27.75 Million USD | -1044.52% |
| GlucoTrack, Inc. | 4.9 Million USD | -6376.473% |
| Harvard Bioscience, Inc. | 137.36 Million USD | -131.259% |
| Hologic, Inc. | 9.15 Billion USD | 96.53% |
| ICU Medical, Inc. | 4.37 Billion USD | 92.745% |
| Intuitive Surgical, Inc. | 15.44 Billion USD | 97.943% |
| KORU Medical Systems, Inc. | 28.46 Million USD | -1016.164% |
| LeMaitre Vascular, Inc. | 346.77 Million USD | 8.394% |
| Innovative Eyewear, Inc. | 6.21 Million USD | -5008.268% |
| Innovative Eyewear, Inc. | 6.21 Million USD | -5008.268% |
| Masimo Corporation | 3.04 Billion USD | 89.555% |
| Microbot Medical Inc. | 8.32 Million USD | -3714.951% |
| Meihua International Medical Technologies Co., Ltd. | 171.91 Million USD | -84.783% |
| Merit Medical Systems, Inc. | 2.32 Billion USD | 86.338% |
| Nephros, Inc. | 11.86 Million USD | -2578.282% |
| NovoCure Limited | 1.14 Billion USD | 72.283% |
| NEXGEL, Inc. | 9.95 Million USD | -3091.07% |
| NEXGEL, Inc. | 9.95 Million USD | -3091.07% |
| Singular Genomics Systems, Inc. | 265.46 Million USD | -19.665% |
| OraSure Technologies, Inc. | 482.84 Million USD | 34.208% |
| Pro-Dex, Inc. | 54.21 Million USD | -486.001% |
| Pulse Biosciences, Inc. | 60.8 Million USD | -422.451% |
| Predictive Oncology Inc. | 14.41 Million USD | -2103.409% |
| Precision Optics Corporation, Inc. | 16.91 Million USD | -1778.313% |
| QuidelOrtho Corporation | 8.56 Billion USD | 96.29% |
| Repligen Corporation | 2.82 Billion USD | 88.753% |
| Sanara MedTech Inc. | 73.87 Million USD | -330.034% |
| STAAR Surgical Company | 488.69 Million USD | 34.996% |
| Sharps Technology, Inc. | 11.78 Million USD | -2594.578% |
| Utah Medical Products, Inc. | 135.45 Million USD | -134.516% |
| DENTSPLY SIRONA Inc. | 7.37 Billion USD | 95.69% |
| Jin Medical International Ltd. | 32.9 Million USD | -865.464% |